Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Tilray Brands Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.52 (market cap $5.07B), while Tilray Brands Inc trades at $4.78 (market cap $649.42M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 7.8× Tilray Brands Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | TLRY | |
|---|---|---|
Market Cap | $5.07B | $649.42M |
Sector | Health | Health |
52-Week High | $29.41 | $21.00 |
52-Week Low | $20.06 | $3.88 |
Enterprise Value | $4.19B | $816.55M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
